PROTECT-1: A prospective randomized trial of CCX282-B (Traficet-EN), a novel oral therapy targeting chemokine receptor 9 in Crohn's disease

Bibliographic Details
Main Authors:	Keshav, S, Petryka, R, Vanask, T, Niv, Y, Marlicz, K, Haagen-Nielsen, O, Machado, M, Dahlerup, J, Schreiber, S, Bekker, P, Sankar, S, Schall, T
Format:	Conference item
Published:	2007

Similar Items